| Hazard Arh Regional Medical Center | |
|
100 Medical Center Dr Hazard KY 41701-9421 | |
| (606) 439-1331 | |
| (606) 439-6629 |
| Full Name | Hazard Arh Regional Medical Center |
|---|---|
| Speciality | Psychiatric Unit |
| Location | 100 Medical Center Dr, Hazard, Kentucky |
| Authorized Official Name and Position | Hollie Harris (PRESIDENT AND CEO) |
| Authorized Official Contact | 8592262511 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Hazard Arh Regional Medical Center 100 Medical Center Dr Hazard KY 41701-9421 Ph: (606) 439-1331 | Hazard Arh Regional Medical Center 100 Medical Center Dr Hazard KY 41701-9421 Ph: (606) 439-1331 |
| NPI Number | 1730172057 |
|---|---|
| Provider Enumeration Date | 08/23/2005 |
| Last Update Date | 05/18/2021 |
| Certification Date | 05/18/2021 |
| Medicare PECOS PAC ID | 0840107835 |
|---|---|
| Medicare Enrollment ID | O20071204000784 |
News Archive
One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Researchers from the brain cognition and plasticity group of the Bellvitge Biomedical Research Institute and the Neuroscience Institute of the University of Barcelona have led an innovative study that identifies modifications in the connectivity of cerebral white matter associated with the heterogeneous nature of apathy in Huntington's disease, making it possible to use this syndrome as a biomarker of disease progression.
Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730172057 | NPI | - | NPPES |
| 303796 | Other | FEDERAL BLACK LUNG | |
| 000000054397 | Other | KY | ANTHEM BC |
| 303796 | Other | KY | FEDERAL BLACK LUNG |
| 18S029 | Other | KY | MEDICARE RAILROAD |
| 92000017 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 273R00000X | Psychiatric Unit | 100365 (Kentucky) | Primary |
News Archive
One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.
Researchers from the brain cognition and plasticity group of the Bellvitge Biomedical Research Institute and the Neuroscience Institute of the University of Barcelona have led an innovative study that identifies modifications in the connectivity of cerebral white matter associated with the heterogeneous nature of apathy in Huntington's disease, making it possible to use this syndrome as a biomarker of disease progression.
Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
› Verified 9 days ago
C Krishnaswamy Md Psc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Medical Center Dr, Suite 3p, Hazard, KY 41701 Phone: 606-487-7955 | |
Uk Family Practice-hazard Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Airport Gardens Rd, Suite 7, Hazard, KY 41701 Phone: 859-257-7922 | |
Directions Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2006 W Ky Hwg 80, Hazard, KY 41701 Phone: 606-439-6084 Fax: 606-439-6084 | |
Best Life, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 98 Joe Fields Lane, Hazard, KY 41701 Phone: 606-657-1642 | |
Uk North Fork Valley Community Health Center Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 750 Morton Blvd, Hazard, KY 41701 Phone: 606-439-1559 | |
Arh Pain Management And Headache Medicine Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 200 Medical Center Dr Ste 3l, Hazard, KY 41701 Phone: 606-439-6600 | |
Courage To Change Corp Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2785 N Main St Ste 101b, Hazard, KY 41701 Phone: 606-224-8451 |